Showing results (211-220 of 270) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myelomaMarco Ladetto, Gloria Pagliano, Simone Ferrero, et al.
Diagnostics (Basel, Switzerland)|April 30, 2021
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine ImplementationMartina Ferrante, Daniela Furlan, Silvia Zibellini, et al.
Cancer Medicine|July 20, 2024
Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER studyIrene Dogliotti, Veronica Peri, Michele Clerico, et al.
Haematologica|March 24, 2018
Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemiaDaniela Drandi, Elisa Genuardi, Irene Dogliotti, et al.
Nature Communications|November 22, 2017
The IKK/NF-κB signaling pathway requires Morgana to drive breast cancer metastasisFederica Fusella, Laura Seclì, Elena Busso, et al.
Blood|June 19, 2013
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated resultsFrancesca Gay, Valeria Magarotto, Claudia Crippa, et al.
Blood|January 9, 2019
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCLMagdalena Klanova, Laurie H Sehn, Isabelle Bence-Bruckler, et al.
Cancers|August 26, 2022
HER2-Displaying M13 Bacteriophages induce Therapeutic Immunity against Breast CancerJunbiao Wang, Alessia Lamolinara, Laura Conti, et al.
Blood|January 14, 2011
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsFrancesca Gay, Alessandra Larocca, Pierre Wijermans, et al.
British Journal of Haematology|January 24, 2014
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patientsAlberto Rocci, Manuela Gambella, Simona Aschero, et al.
Pageof 27